Every year, National Adverse Drug Event Awareness Day serves as a critical reminder of a persistent—and often underrecognized—challenge in healthcare: medications, while lifesaving, can also cause harm. Adverse drug events (ADEs) are responsible for millions of injuries annually, leading to avoidable hospitalizations, increased medical costs, and diminished quality of life—particularly among older adults and other individuals with complex medication regimens. According to the American Society of Pharmacovigilance, ADEs are the 3rd leading cause of death in the United States, behind only heart disease and cancer.
For PACE organizations, ADEs represent more than a clinical issue. They are a systems-level challenge that touches every dimension of care: patient safety, financial performance, and operational efficiency.
An ADE is any harm experienced by a participant as a result of medication use. This includes side effects, multi-drug interactions, dosing errors, and complications arising from inappropriate prescribing. While ADEs can affect anyone, they disproportionately impact high-risk populations—especially older adults with multiple chronic conditions. According to the Lown Institute,
Polypharmacy significantly increases the likelihood of ADEs. In PACE populations, where participants may take 10, 15, or even more medications daily, the risk compounds rapidly. The result is more medications, more complexity, and more opportunity for harm.
The healthcare industry has long recognized the risks associated with medications, yet ADEs remain one of the leading causes of preventable harm.
Why?
Traditional approaches to medication management are often fragmented, reactive, and insufficiently personalized. Medication reviews are not always informed by the latest evidence, advanced analytics, or a comprehensive understanding of how drugs interact within an individual patient’s unique biological and clinical context. In fact, most healthcare systems still rely on the outdated, binary 1:1 drug interaction checks that have been in place since the 1970s.
In many healthcare models, there are multiple specialists per patient, without coordinated oversight of the patient as a whole. Yet even in PACE, where an interdisciplinary, whole-person approach is at the core of the model, there hasn’t been an easy way to integrate the latest science directly into everyday workflows in a way that improves medication safety while decreasing operational burden.
At GalenusCare, we believe that predicting and preventing ADEs requires a fundamentally different approach—one that integrates advanced science, modern technology, and pharmacist collaboration. Our ChorusRx practice model is built around a simple but powerful proposition: medication safety should be proactive, personalized, and continuously optimized at the point of care.
This begins with advanced, AI-powered risk analytics, which evaluate not only individual drugs but the full regimen—identifying cumulative drug burden and simultaneous multi-drug interactions in real-time. These insights are further enhanced by pharmacogenomic (PGx) data, allowing clinicians to understand how a patient’s genetic profile may influence drug metabolism and response.
From there, our clinical pharmacists work in close collaboration with interdisciplinary care teams to optimize medication regimens—reducing unnecessary medications, adjusting therapies, and aligning treatment plans with each participant’s goals of care.
Our clinical insights flow directly into precision dispensing systems, where medications are packaged by optimal time-of-day to minimize multi-drug interactions and support adherence. This ensures “pull-through” of the optimized regimen—bridging the gap between clinical decision-making and real-world medication use.
For PACE organizations and other value-based providers, the implications are significant.
Preventing ADEs leads to:
Just as importantly, it transforms medication management from a source of risk into a driver of performance. In PACE and other full-risk, capitated models, every adverse event is not only a clinical setback but also a financial one. Organizations that can effectively manage medication risk will be better positioned to succeed—clinically, operationally, and economically.
The future of medication safety is predictive, precise, and person-centered.
On this National ADE Awareness Day, the question is no longer whether we understand the problem. It’s whether we are ready to solve it at scale.
What would it look like to prevent harm before it happens—consistently, proactively, and for every participant?
That is the future ChorusRx is designed to deliver.